v3.26.1
Segment Reporting (Tables)
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
The table below summarizes the significant expenses regularly reviewed by the CODM (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Total revenue (a)$32,832 $6,869 $39,553 $13,911 
Research and development expenses:
MGC02810,179 4,742 16,573 8,676 
MGC0267,198 2,961 14,003 8,914 
Lorigerlimab6,120 10,547 13,579 19,425 
Next-generation T-cell engagers5,987 3,516 10,635 5,789 
MGC0305,001 5,666 8,930 8,172 
MGD0242,082 2,715 4,858 4,907 
Vobramitamab duocarmazine198 4,387 585 12,653 
Preclinical antibody-drug conjugates (ADCs)26 2,058 89 3,857 
Other programs1,989 4,199 4,502 8,096 
Total research and development expenses38,780 40,791 73,754 80,489 
General and administrative expenses7,904 9,302 17,614 20,020 
Other segment income (loss), net (b)(55,790)507 (59,125)2,094 
Net loss from continuing operations$(69,642)$(42,717)$(110,940)$(84,504)
(a) Total revenue includes collaborative and other agreements and royalty revenue.
(b) Other segment income (loss), net includes interest and other income and interest and other expense, and for the three and six months ended June 30, 2026 the loss on extinguishment of royalty monetization liability.